The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Practical Approach for Gliomas, Part 1. Basic Tumor Genetics

Arevalo, O.J.; Valenzuela, R.; Esquenazi, Y.; Rao, M.; Tran, B.; Zhu, J.; Bhattacharjee, M.; Fonseca, P.; Doyle, N.; Riascos, R.F.

View Article on Neurographics Website

Date of Activity Release: Oct. 1, 2017
Date of Activity Expiration: Oct. 1, 2020

Target Audience:
Intended for neuroradiologists and neuroradiology trainees with varying degrees of experience.

Learning Objective:
Identify the role of isocitrate dehydrogenase status in the new World Health Organization classification of gliomas and its importance regarding natural history and prognosis.

CNS gliomas are a heterogeneous group of tumors that exhibit different behaviors clinically, and pathologic identification categorizes them into groups with similar prognosis and subsequent treatment. The World Health Organization published the fourth edition of the classification for CNS tumors in 2014 and presented a new update in May 2016. This latest update integrates recent advances and results in glioma tumorigenesis at the molecular level with previous histopathologic classification. It also removes terms that were found not clinically useful. This article offers a practical review of glioma molecular profiles and their importance in the latest classification and changes of nomenclature. Representative imaging features on MR imaging and illustrative cases are also included.

Commercial Support
No commercial support was received for this activity.

Credit Designation Statement

The American Society of Neuroradiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Neuroradiology designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Physician Participation:
Each participant will review the corresponding Neurographics article located at Upon completion, each physician will complete and pass a post-test with a score of at least 80% to receive a CME certificate.

All individuals in control of content have disclosed the following relevant financial relationships. All of these relationships were treated as a conflict of interest, and have been resolved (C7 SCS 6.1-6.2, 6.5)

Authors have no relevant financial relationships.





Barton Branstetter 

Editor in Chief

None, N/A

Adam Flanders

Deputy Editor

Royalties, Lippincott Williams and Wilkins

Robert Quencer 

Consulting Editor

None, N/A

Mark Mullins

Associate Editor

Non-remunerative position, AUR6

Meng Law

Associate Editor

Stockholder, Clinical Imaging

Michele Johnson

Associate Editor

Consultant, Boston Scientific, Inc.

Edward Escott

Associate Editor

Grant, Atherysys, Inc.; Royalties, Thieme Medical Publishers

Scott Faro

Associate Editor

None, N/A

Tina Young Poussaint

Associate Editor

None, N/A

Dheeraj Ghandi

Associate Editor

Grant, Arstasis, Axera Inc.; Consultant, Covidien, EV3

Contact Information:
If you have questions regarding this enduring material activity, please contact us at

Privacy Policy and Confidentiality Policy:
The ASNR does not share your personal information provided to this site with any third party, except where required by CME governing bodies for verification of CME activities. Your email address will only be used to contact you in relation to your activities on the website, except where you have given ASNR permission to contact you with additional information. ASNR adheres to the same policy for members as nonmembers, except that: ASNR member mailing address information may be shared with providers of accredited CME activities.

Copyright © American Society of Neuroradiology, 2011-2017